This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion: Sirna

Shares of Rockwell Medical Technologies (RMTI) were up 24% after the hemodialysis products maker said second-quarter sales increased 77.8% over last year. Net income in the second quarter was $85,456, or 1 cent a share. Separately, the company said the European Patent and Trademark Office will issue a patent for its proprietary iron delivery product. Rockwell was up 77 cents to $3.97.

China Medical Technologies (CMED) was gaining 15% on its first day of trading after pricing an initial public offering at $15 a share. Shares of the China-based medical devices company were up $2.30 to $17.30.

Coley Pharmaceutical Group (COLY) rose nearly 18% after selling shares in an initial public offering at $16 each. The biopharmaceutical company's stock was rising $2.83 to $18.83.

KV Pharmaceutical (KV.A) was climbing 6.5% after the company's revenue for the first quarter rose 29% to $85.5 million. After a writeoff of 62 cents a share for a product acquisition, the company lost 45 cents a share. Excluding this writeoff, adjusted earnings for the first quarter would have been $8.5 million, or 16 cents a share, topping estimates by 3 cents. The specialty pharmaceutical company rose $1.06 to $17.15.

Curative Health Services (CURE) dropped 28% after the company posted revenue of $71.6 million and a loss was $4.8 million, or 37 cents a share, for the second quarter. Before items, the company would have lost 31 cents. Curative shares lost 96 cents to $2.52.

CuraGen (CRGN) sank nearly 14% after the biopharmaceutical company priced a public offering of 4 million shares at $5.50 each. The proceeds of the offering will be about $21 million. Shares of CuraGen were down 82 cents to $5.24.

Sirna Therapeutics (RNAI) fell 8% after reporting a loss of $5.9 million, or 14 cents a share, for the second quarter. Revenue for the second quarter was $1.5 million. Shares of the clinical-stage biotechnology company were losing 34 cents to $3.76.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs